Biotech & Health Tech
VectorY bags $83.5M for antibody gene therapies in neurodegenerative diseases
VectorY Therapeutics added €74.5 million ($83.5 million) to its Series A to fund a gene therapy that makes antibodies in the brain. The biotech’s lead asset VTx-002 is in a
VectorY Therapeutics added €74.5 million ($83.5 million) to its Series A to fund a gene therapy that makes antibodies in the brain. The biotech’s lead asset VTx-002 is in a
This is a summary of the story. Read the full article at Endpoints News (Biopharma) ↗